HopeStage
Back to all studies
CompletedNCT01452919

Dependence Symptoms After Stopping LY2140023 in Schizophrenia

About this titleRead the official source — NCT01452919
Medication studyAges 18–65United States + Greece
The study in practice

Understand this study

Who was this study for?

This study was for people with schizophrenia. Listed age limits: 18 years to 65 years. Other eligibility criteria applied.

Listed locations
Oakland and 9 more locationsSee all locations and recruitment
Study phase
Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.

Get this study by email

HopeStage may email me about this study.
Loading the security check...
Study clarity

Study information

Study start dateNovember 2011
Recruitment status
Completed
Enrollment listed in the registry
123
Sponsor
Denovo Biopharma LLC
Sponsor type
Biotech company
Study type
Drug
Intervention type
Drug
Study phase
Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
Locations
United States, Greece
Age range
From 18 Years to 65 Years
Official registry ID
NCT01452919
Official title
Show the full official title

A Phase 3, Short-Term, Multicenter, Placebo-Controlled, Randomized Withdrawal Study of LY2140023 Monohydrate in Patients With DSM-IV-TR Schizophrenia

Looking for a study you can join?

Explore recruiting studies

Recruitment & locations

Completed

Oakland, United States · San Diego, United States · Torrance, United States

7 more locations
  • North Miami, United States
  • Lake Charles, United States
  • Flowood, United States
  • Philadelphia, United States
  • Bellevue, United States
  • Chaïdári, Greece
  • Tripoli, Greece

Interested in joining this study?

HopeStage may email me about this study.
Loading the security check...
FAQ

Questions about this study

Who is behind this study?

The study sponsor is Denovo Biopharma LLC.

Did this study involve medication?

Yes. The study involved medication, including LY2140023 and Placebo.

Who was this study for?

This study was for people with schizophrenia. Listed age limits: 18 years to 65 years. Other eligibility criteria applied.

Want to explore more studies?

Explore studies